secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058242
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Q1 2024 net loss $5.9M; EVANGELINE 100% disease control at 24 weeks
--------------------------------------------------------------------------

- Net loss of $5.9M (operating expenses $7.0M, interest income $1.1M); cash $84.0M, no debt.
- EVANGELINE study: 100% disease control rate, 37% avg lesion size reduction, 92% Ki-67 drop at 24 weeks.
- Initiated combination study of (Z)-endoxifen + abemaciclib in ER+/HER2- breast cancer (20 patients).
- I-SPY 2 Phase 2 trial fully enrolled; data readout expected in H2 2024.
- Appointed medical oncologist Dr. Tessa Cigler to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024058242/0000950170-24-058242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024058242/atos-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer